89bio’s PhII da­ta add to quick suc­ces­sion of NASH read­outs as field seeks turn­around

89bio said its drug was bet­ter than place­bo at less­en­ing fi­bro­sis with­out wors­en­ing non­al­co­holic steato­hep­ati­tis, or NASH, in two of three dose groups.

The San Fran­cis­co biotech said it thinks the Phase IIb da­ta pave the way for a po­ten­tial Phase III, fol­low­ing in the foot­steps of an­oth­er biotech in its drug class, Akero Ther­a­peu­tics. To fund a late-stage study, CEO Ro­han Palekar told End­points News 89bio “would need to raise ad­di­tion­al cap­i­tal,” with the com­pa­ny hav­ing about $188 mil­lion at the end of last year.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN